Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIREFLEYE Next long-term extension in retinopathy of prematurity
NL-OMON49661Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of aflibercept in retinopathy of prematurity (ROP) (2 arms), sponsored by Bayer. Primary endpoints: Binocular best-corrected visual acuity, Ocular adverse events and 1 more. Started Dec 2020; status: active, not recruiting.
02
Drugs
aflibercept
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NL-OMON49661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49661.